Vascular Endothelial Growth Factor and Diabetic Retinal Disease

REFERENCES

• Federation, International Diabetes. Diabetes: Facts and figures. 2015. http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures (accessed August 23, 2014)
   Google Scholar
• Bain SC, Gill GV, Dyer PH, et al. Characteristics of Type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med 2003;20:808–811
   PubMed Web of Science ®Google Scholar
• Keenan HA, Costacou T, Sun JK, et al. Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: The 50-year medalist study. Diabetes Care 2007;30:1995–1997
   PubMed Web of Science ®Google Scholar
• Fong DS, Aiello LP, Ferris FL III, et al. Diabetic retinopathy. Diabetes Care 2004;27:2540–2553
   PubMed Web of Science ®Google Scholar
• Wiley HE, Ferris FL III. Nonproliferative diabetic retinopathy and diabetic macular edema. In: Retina. Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, Ryan SJ, et al., eds., 5th eds. New York: Elsevier, 2013. 940–968
   Google Scholar
• Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552–563.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Varma R, Doan QV, et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol 2014;132:168–173
   PubMed Web of Science ®Google Scholar
• Fareed A. A review of diabetic macular edema. Digital J Ophthalmol 1997;3:1–8
   Google Scholar
• Ferris FL III, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28(suppl):452–461
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7–16
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464–1474
   PubMed Web of Science ®Google Scholar
• Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796–1806
   PubMed Web of Science ®Google Scholar
• Ferrara N, Houck KA, Jakeman LB, et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991;47:211–218
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985
   PubMed Web of Science ®Google Scholar
• Senger D, Connoly D, Van De Water L, et al. Purification and NH2-terninal amino acid sequence of guinea pig tumor–secreted vascular permeability factor. Cancer Res 1990; 50:1774–1778
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487
   PubMed Web of Science ®Google Scholar
• Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445–450
   PubMed Web of Science ®Google Scholar
• Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538–1544
   PubMed Web of Science ®Google Scholar
• Aiello, LP, Pierce EA, Foley ED, et al. Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc Natl Acad Sci USA 1995;92:10457–10461
   PubMed Web of Science ®Google Scholar
• Robinson GS, Pierce EA, Rook SL, et al. Ligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA 1996;93:4851–4856
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of VEGF prevent ocular neovascularization in a nonhuman primate. Arch Ophthalmol 1996;114:66–71
   PubMed Web of Science ®Google Scholar
• Aiello, LP. Vascular endothelial growth factor. 20th-Century mechanisms, 21st-century therapies. Invest Ophthalmol Vis Sci 1997;38:1647–1652
   PubMed Web of Science ®Google Scholar
• Zhang X, Zeng H, Bao S, et al. Diabetic macular edema: New concepts in patho-physiology and treatment. Cell Biosci 2014;4:27
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011;118:672–678
   PubMed Web of Science ®Google Scholar
• Avery, RL. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:352–354
   PubMed Web of Science ®Google Scholar
• Zhang X, Bao S, Hambly BD, et al. Vascular endothelial growth factor-A: A multifunctional molecular player in diabetic retinopathy. Int J Biochem Cell Biol 2009;41:2368–2371
   PubMed Web of Science ®Google Scholar
• Ciombor KK, Berlin J, Chan E. Aflibercept. Clin Cancer Res 2013;19:1920–1925
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema. March 27, 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439838.htm (accessed June 12, 2015)
   Google Scholar
• Hanout M, Ferraz D, Ansari M. Therapies for neovascular age-related macular degeneration: Current approaches and pharmacologic agents in development. Biomed Res Int 2013;2013:830–837
   Web of Science ®Google Scholar
• Conbercept requires lower dosing frequency, provides visual acuity improvements equal to other anti-VEGF agents. Retina Today March 14, 2014. http://retinatoday.com/2014/03/14/conbercept-requires-lower-dosing-frequency-provides-visual-acuity-improvements-equal-to-other-anti-vegf-agents (accessed May 18, 2015)
   Google Scholar
• Li X, Xu G, Wang Y, Xu X, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: Results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 2014;121:1740–1747
   PubMed Web of Science ®Google Scholar
• AAO recap. Retina Today November/December 2014. http://retinatoday.com/2014/12/aao-recap/ (accessed June 11, 2015)
   Google Scholar
• Michaelides M, Kaines A, Hamilton RD. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010;117:1078–1086
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-Month data: Report 3. Arch Ophthalmol 2012; 130:972–979
   PubMed Web of Science ®Google Scholar
• Jampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA 2014;311:2269–2270
   PubMed Web of Science ®Google Scholar
• Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011;118:609–614
   PubMed Web of Science ®Google Scholar
• Elman MJ, Qin H, Aiello LP, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment. Ophthalmology 2012;119:2312–2318
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema following focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011;31:1009–1027
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014;121:2247–2254
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015;372:1193–1203
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Hopkins JJ, et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 2012;130:1145–1152
   PubMed Web of Science ®Google Scholar
• Ip MS, Domalpally A, Sun JK, et al. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology 2015;122:367–374
   PubMed Web of Science ®Google Scholar
• Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695e1–169515
   Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol 2013;131:283–293
   PubMed Web of Science ®Google Scholar
• Bhavsar AR, Torres K, Glassman AR, et al. Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy. JAMA Ophthalmol 2014;132:889–890
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Prompt panretinal photocoagulation versus ranibizumab + deferred panretinal photocoagulation for proliferative diabetic retinopathy (protocol S). https://clinicaltrials.gov/ct2/show/NCT01489189?term=protocol+S&rank=1 (accessed May 18, 2015)
   Google Scholar
• Diabetic Retinopathy Clinical Research Network (DRCRnet) public website. http://drcrnet.jaeb.org/Publications.aspx (accessed June 11, 2015)
   Google Scholar
• Aiello LP, Beck RW, Bressler NM, et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 2011;118:e5–e14
   PubMed Web of Science ®Google Scholar